3M and VaxInnate Collaborate to Develop Flu Vaccine Patch

23-Oct-2008 - USA

3M drug delivery Systems has entered into an agreement with VaxInnate Corporation to develop a flu vaccine patch for use against a pandemic flu outbreak. The non-exclusive license agreement provides VaxInnate with use of patented 3M microneedle technology, called 3M Microstructured Transdermal System (MTS) technology, to deliver its M2e universal flu vaccine using a convenient skin patch instead of a traditional injection.

“Our technology combines the ease, convenience and self-administration potential of a transdermal patch with the speed and efficiency of a traditional injection,” said Kris Hansen, PhD, MTS Technical Manager for 3M Drug Delivery Systems. “Studies using model vaccines have validated the potential effectiveness of delivering vaccines with the solid Microstructured Transdermal System.”

“The ability to deliver VaxInnate’s M2e universal flu vaccine using 3M’s transdermal patch could make it possible to vaccinate people rapidly for seasonal flu or in the event of a pandemic flu, when doing so is critical to stopping the spread of disease,” added Alan Shaw PhD, VaxInnate CEO. “Through this collaboration, we have an opportunity to make a major contribution to global public health.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances